支气管动脉灌注联合125I粒子植入治疗中晚期肺癌的临床研究

摘要

目的:探讨支气管动脉灌注联合125 I放射性粒子植入治疗中晚期肺部恶性肿瘤的临床疗效.方法:对102例中晚期肺癌患者分为两组.A组57例支气管动脉灌注联合125 I放射性粒子植入治疗；B组45例支气管动脉灌注治疗.术后4周开始行CT随访,根据实体瘤疗效评价标准(RECIST)及患者生存时间评价两组的疗效.结果:术后12个月两组有效率(CR+PR)分别为83.3％、46.7％:A、B两组有显著性差异(P＜0.05)；术后6个月、12个月和24个月生存率A组为91.2％.82.5％.63.2％.明显高于B组的60％.33.3％.6.7％(P＜0.05).结论:支气管动脉灌注联合125 I放射性粒子植入治疗中晚期肺癌是一种疗效显著、微创、安全的方法,是现阶段治疗中晚期肺癌的新选择.%Objective:To assess the clinical application of bronchial artery infusion with 125I radioactive seed implantation for the treatment of advanced lung cancer. Methods: 102 patients with advanced lung cancer were collected and randomized into two groups, I.e. groupA. Bronchial artery infusion with 125I radioactive seed implantation in 57 patients. GroupB. Bronchial artery infusion in 45 patients. The therapeutic efficacy was evaluated according to REC1ST standards and the survival rates of 102 cases. Results:CR plus PR of group B was 45. 2% at 12 months, and the difference between guoup A (83.3%) were statistical significance ( P <0. 05); survival rates of 6, 12,24 months in group A (91. 7%, 83.3%. 63. 2%) were higher than that in group B (59. 3%, 33. 3%. 6. 7%)( P <0. 05). Conclusion:Bronchial artery infusion with 125I radioactive seed implantation is a effective, minimally invasive and safe therapy for advanced lung cancer.